<DOC>
	<DOC>NCT02558894</DOC>
	<brief_summary>A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.</brief_summary>
	<brief_title>Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma</brief_title>
	<detailed_description>This is a Phase II, open-label, multi-center study to determine the efficacy and safety of MEDI4736 evaluated as single agent or in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) whose disease has progressed on fluoropyrimidine containing or gemcitabine-containing first-line chemotherapy.This study will consist of Part A, lead-in, as well as a possible expansion Part B.</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>1. Histologically or cytologically confirmed metastatic PDAC, no more than 1 prior chemotherapy regimen 2. Eastern Cooperative Oncology Group 0 or 1 3. At least 1 lesion, not previously irradiated, that can be accurately measured at baseline as ≥10 mm in the longest diameter (except lymph nodes, which must have short axis ≥15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) scan and that is suitable for accurate repeated measurements 1. Any concurrent chemotherapy, investigational product , biologic, or hormonal therapy for cancer treatment. 2. History of leptomeningeal carcinomatosis 3. Ascites requiring intervention 4. Brain metastases or spinal cord compression.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pancreatic Ductal Adenocarcinoma, PDAC</keyword>
</DOC>